| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
The two BCN groups react with azide-containing molecules via copper-free click chemistry (SPAAC). The hydrophilic PEG spacer increases solubility in aqueous media. This is a cleavable (degradable) ADC linker that enables dual conjugation of biomolecules.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
In vitro activity is primarily related to its function as an ADC linker. bis-PEG2-endo-BCN enables the conjugation of antibodies to cytotoxic payloads via click chemistry. The PEG spacer provides aqueous solubility and flexibility. Click reaction efficiency is assessed by HPLC, mass spectrometry, or gel electrophoresis. |
| ln Vivo |
In vivo activity of bis-PEG2-endo-BCN is primarily inferred from its use in ADC development. ADCs synthesized using this linker deliver therapeutic agents to specific cells or tissues. The cleavable nature allows for payload release at the target site. No direct in vivo activity data are specifically available for this linker alone.
|
| Enzyme Assay |
In vitro assays for bis-PEG2-endo-BCN typically involve evaluating click chemistry reactivity with azide-containing molecules. Reaction efficiency is assessed by HPLC, mass spectrometry, or gel electrophoresis. Purity is assessed by HPLC. Solubility is evaluated in aqueous and organic solvents. The compound is characterized by NMR and mass spectrometry.
|
| Cell Assay |
Cell-based assays for bis-PEG2-endo-BCN are conducted in the context of ADC activity. Target cells expressing the antigen of interest are treated with ADCs synthesized using this linker. Cytotoxicity is measured by MTT or CellTiter-Glo assays. Antigen-specific cell killing is compared to non-targeting controls. Internalization and trafficking of ADCs are assessed by immunofluorescence microscopy.
|
| Animal Protocol |
In vivo animal studies for bis-PEG2-endo-BCN are conducted in the context of ADC efficacy. Tumor-bearing mice are treated with ADCs synthesized using this linker, and tumor growth inhibition is monitored. Pharmacokinetic parameters are evaluated by measuring ADC levels in blood and tissues. Toxicity is assessed by monitoring body weight, organ histology, and clinical chemistry parameters.
|
| ADME/Pharmacokinetics |
As a PEG-based linker (molecular weight 500.64, formula C28H40N2O6), bis-PEG2-endo-BCN has favorable aqueous solubility due to the hydrophilic PEG spacer. The BCN groups are stable under physiological conditions. No specific PK data are available for this linker alone; its PK profile is determined by the conjugated molecule.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for bis-PEG2-endo-BCN. The compound is for research use only and not intended for therapeutic use. Standard laboratory safety precautions should be followed. Comprehensive toxicological evaluation has not been reported.
|
| References | |
| Additional Infomation |
Bis-PEG2-endo-BCN (CAS#: 1476737-97-9) is a bifunctional ADC linker with two endo-BCN groups connected via a PEG2 spacer. It is used for dual strain-promoted azide-alkyne click conjugations in ADC synthesis. Molecular weight: 500.64, formula: C28H40N2O6. It is for research use only and not an approved therapeutic agent.
|
| Molecular Formula |
C28H40N2O6
|
|---|---|
| Molecular Weight |
500.62700843811
|
| Exact Mass |
500.288
|
| CAS # |
1476737-97-9
|
| PubChem CID |
98813933
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
36
|
| Complexity |
772
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1C[C@@H]2[C@@H](C2COC(=O)NCCOCCOCCNC(=O)OCC3[C@H]4[C@@H]3CCC#CCC4)CCC#C1
|
| InChi Key |
NISHVKOYJUQOBR-ICFBRBJFSA-N
|
| InChi Code |
InChI=1S/C28H40N2O6/c31-27(35-19-25-21-9-5-1-2-6-10-22(21)25)29-13-15-33-17-18-34-16-14-30-28(32)36-20-26-23-11-7-3-4-8-12-24(23)26/h21-26H,5-20H2,(H,29,31)(H,30,32)/t21-,22+,23-,24+,25?,26?
|
| Chemical Name |
[(1R,8S)-9-bicyclo[6.1.0]non-4-ynyl]methyl N-[2-[2-[2-[[(1R,8S)-9-bicyclo[6.1.0]non-4-ynyl]methoxycarbonylamino]ethoxy]ethoxy]ethyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~199.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.99 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9975 mL | 9.9874 mL | 19.9748 mL | |
| 5 mM | 0.3995 mL | 1.9975 mL | 3.9950 mL | |
| 10 mM | 0.1997 mL | 0.9987 mL | 1.9975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
